Published in Can J Gastroenterol on August 01, 2003
What is the empirical evidence that hospitals with higher-risk adjusted mortality rates provide poorer quality care? A systematic review of the literature. BMC Health Serv Res (2007) 3.02
Validation of the Rockall scoring system for outcomes from non-variceal upper gastrointestinal bleeding in a Canadian setting. World J Gastroenterol (2006) 0.99
Impact of anti-aggregant, anti-coagulant and non-steroidal anti-inflammatory drugs on hospital outcomes in patients with peptic ulcer bleeding. Saudi J Gastroenterol (2014) 0.75
Predictors of ICU Admission and Outcomes 1 Year Post-Admission in Persons with IBD: A Population-based Study. Inflamm Bowel Dis (2015) 0.75
Diversity of the human intestinal microbial flora. Science (2005) 49.64
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77
Risk of developing colorectal cancer following a negative colonoscopy examination: evidence for a 10-year interval between colonoscopies. JAMA (2006) 6.26
How many duodenal biopsy specimens are required to make a diagnosis of celiac disease? Gastrointest Endosc (2008) 4.58
Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ (2008) 4.12
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology (2005) 4.06
The reduction in colorectal cancer mortality after colonoscopy varies by site of the cancer. Gastroenterology (2010) 3.87
Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol (2010) 3.12
Rate and predictors of early/missed colorectal cancers after colonoscopy in Manitoba: a population-based study. Am J Gastroenterol (2010) 2.97
Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med (2005) 2.68
Work losses related to inflammatory bowel disease in Canada: results from a National Population Health Survey. Am J Gastroenterol (2003) 2.63
Randomized trial of medical or endoscopic therapy to prevent recurrent ulcer hemorrhage in patients with adherent clots. Gastroenterology (2002) 2.62
Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut (2012) 2.60
Frequency of colorectal cancer screening and the impact of family physicians on screening behaviour. CMAJ (2007) 2.60
Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol (2005) 2.50
Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol (2007) 2.46
High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut (2006) 2.43
Predictors of colorectal cancer after negative colonoscopy: a population-based study. Am J Gastroenterol (2009) 2.36
Association between the use of antibiotics and new diagnoses of Crohn's disease and ulcerative colitis. Am J Gastroenterol (2011) 2.32
Information needs and preferences of recently diagnosed patients with inflammatory bowel disease. Inflamm Bowel Dis (2011) 2.31
The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med (2003) 2.30
Endoscopic screening for esophageal varices in cirrhosis: Is it ever cost effective? Hepatology (2003) 2.24
Stress coping, distress, and health perceptions in inflammatory bowel disease and community controls. Am J Gastroenterol (2009) 2.22
Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology (2011) 2.22
An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol (2010) 2.18
Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis (2009) 2.15
Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD? Am J Gastroenterol (2009) 2.05
Prokinetics in acute upper GI bleeding: a meta-analysis. Gastrointest Endosc (2010) 1.95
Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Am J Gastroenterol (2008) 1.92
AGA technical review on osteoporosis in hepatic disorders. Gastroenterology (2003) 1.89
Is a negative colonoscopy associated with reassurance or improved health-related quality of life in irritable bowel syndrome? Gastrointest Endosc (2005) 1.88
Geographical variability and environmental risk factors in inflammatory bowel disease. Gut (2013) 1.84
Long-term use of statins and risk of colorectal cancer: a population-based study. Am J Gastroenterol (2009) 1.83
World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis (2010) 1.82
Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol (2003) 1.80
Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol (2006) 1.75
Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol (2012) 1.73
The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. Am J Gastroenterol (2008) 1.72
Colonic stent vs. emergency surgery for management of acute left-sided malignant colonic obstruction: a decision analysis. Gastrointest Endosc (2004) 1.70
Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol (2009) 1.67
Randomized trial of argon plasma coagulation vs. multipolar electrocoagulation for ablation of Barrett's esophagus. Gastrointest Endosc (2005) 1.66
Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease. Inflamm Bowel Dis (2007) 1.63
5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations. Am J Gastroenterol (2012) 1.61
Pathological reassessment of hyperplastic colon polyps in a city-wide pathology practice: implications for polyp surveillance recommendations. Gastrointest Endosc (2012) 1.60
Colonoscopy and its complications across a Canadian regional health authority. Gastrointest Endosc (2009) 1.56
Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology (2007) 1.55
Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med (2009) 1.53
The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol (2006) 1.52
Role of biological therapy for inflammatory bowel disease in developing countries. Gut (2011) 1.51
Clinical determinants of health-related quality of life in patients with irritable bowel syndrome. Arch Intern Med (2004) 1.51
Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis. Gastroenterology (2004) 1.49
Crohn's disease recurrence in a small bowel transplant. Am J Gastroenterol (2004) 1.49
Sexual abuse in irritable bowel syndrome: to ask or not to ask -- that is the question. Can J Gastroenterol (2002) 1.47
First-degree relatives of patients with rheumatoid arthritis exhibit high prevalence of joint symptoms. J Rheumatol (2013) 1.44
Screening for cervical and breast cancer among women with inflammatory bowel disease: a population-based study. Inflamm Bowel Dis (2010) 1.43
A population-based study of breastfeeding in inflammatory bowel disease: initiation, duration, and effect on disease in the postpartum period. Am J Gastroenterol (2009) 1.43
Health-related quality of life predicts mortality in patients with advanced chronic liver disease. Clin Gastroenterol Hepatol (2009) 1.42
The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol (2012) 1.42
An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol (2011) 1.42
Brain-gut interactions in inflammatory bowel disease. Gastroenterology (2012) 1.42
Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights. Am J Gastroenterol (2012) 1.40
Fewer polyps detected by colonoscopy as the day progresses at a Veteran's Administration teaching hospital. Clin Gastroenterol Hepatol (2009) 1.39
Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics. Can J Gastroenterol (2013) 1.36
A population-based ecologic study of inflammatory bowel disease: searching for etiologic clues. Am J Epidemiol (2006) 1.33
A population-based study of fatigue and sleep difficulties in inflammatory bowel disease. Inflamm Bowel Dis (2010) 1.32
An evaluation of endoscopic indications and findings related to nonvariceal upper-GI hemorrhage in a large multicenter consortium. Gastrointest Endosc (2008) 1.32
Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.30
AMPK agonist downregulates innate and adaptive immune responses in TNBS-induced murine acute and relapsing colitis. Biochem Pharmacol (2010) 1.29
Health care resource utilization in inflammatory bowel disease. Clin Gastroenterol Hepatol (2006) 1.28
Outcomes of patients with Crohn's disease improved from 1988 to 2008 and were associated with increased specialist care. Gastroenterology (2011) 1.24
Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort. Am J Gastroenterol (2005) 1.23
Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol (2006) 1.23
Distinct and overlapping genetic loci in Crohn's disease and ulcerative colitis: correlations with pathogenesis. Inflamm Bowel Dis (2010) 1.22
Nutrition assessment of patients with inflammatory bowel disease. JPEN J Parenter Enteral Nutr (2007) 1.20
Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol (2006) 1.20
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis (2010) 1.15
The Manitoba IBD Index: evidence for a new and simple indicator of IBD activity. Am J Gastroenterol (2009) 1.15
Are perineal and luminal fistulas associated in Crohn's disease? A population-based study. Clin Gastroenterol Hepatol (2006) 1.15
Nonvariceal upper gastrointestinal bleeding: epidemiology and diagnosis. Gastroenterol Clin North Am (2005) 1.14
Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 1.14
Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis (2009) 1.14
IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010--Inflammatory Bowel Disease Task Force meeting. Inflamm Bowel Dis (2011) 1.14
The effect of irritable bowel syndrome on health-related quality of life and health care expenditures. Gastroenterol Clin North Am (2011) 1.13
The evolving epidemiology of inflammatory bowel disease. Curr Opin Gastroenterol (2009) 1.13
Evaluation of capsule endoscopy in active, mild-to-moderate, overt, obscure GI bleeding. Gastrointest Endosc (2007) 1.11
Are physician-derived disease severity indices associated with health-related quality of life in patients with end-stage liver disease? Am J Gastroenterol (2004) 1.10